USE OF MEK INHIBITORS FOR TREATING INFLAMMATION AND VIRUS INDUCED HEMORRHAGIC SHOCK

WIPO Patent Application WO2002069960

A3

The present invention relates to the use of specific compounds for the treatment and/or prophylaxis of inflammatory conditions. Furthermore, the present invention relates to the use of inhibitors for treating viral infections, particularly to the use of MEK inhibitors, especially MEK1 inhibitors, for prophylaxis and/or treatment of virally induced hemorrhagic fever and/or hemorrhagic shock syndromes, for the treatment of virally induced TNF- PROPORTIONAL mediated diseases, and for regulating and/or inhibiting of virally induced TNF- PROPORTIONAL production. Furthermore, methods for preventing and/or treating of virally induced hemorrhagic fevers and/or hemorrhagic shock syndromes, for regulating and/or inhibiting virally induced TNF- PROPORTIONAL production, and for the treatment of virally induced TNF- PROPORTIONAL mediated diseases are disclosed together with pharmaceutical compositions useful within said methods.

JP2023040169	COVERSIN FOR TREATMENT OF AUTOIMMUNE BLISTERING DISEASE
JP4560551	Tetralin and indane derivatives and their use
JP2004505891	Application of substances that act as chain inhibitors to the Raf / MEK / ERK signaling chain in the production of drugs against DNA and RNA viruses

BEVEC DORIAN (DE)
STROHER UTE (CA)
KLENK HANS-DIETER (DE)
WALLASCH CHRISTIAN (DE)

PCT/EP2002/002467

January 03, 2003

March 06, 2002

Click for automatic bibliography generation  

AXXIMA PHARMACEUTICALS AG (DE)
BEVEC DORIAN (DE)
STROHER UTE (CA)
KLENK HANS-DIETER (DE)
WALLASCH CHRISTIAN (DE)

A61K31/145; A61K31/166; A61K31/167; A61K31/351; A61K31/4439; A61K45/08; A61P7/04; A61P29/00; (IPC1-7): A61K31/351; A61K45/08; A61K31/166; A61K31/145; A61K31/4439; A61P29/00; A61P7/04

WO2000056706A1	2000-09-28
WO2000056725A1	2000-09-28
WO2000040237A1	2000-07-13
WO1998037881A1	1998-09-03

US5525625A	1996-06-11
US6147107A	2000-11-14

JAFFEE BRUCE D ET AL: "Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 268, no. 2, 16 February 2000 (2000-02-16), pages 647 - 651, XP001088905, ISSN: 0006-291X
WARRIOR USHA ET AL: "Development of a p38 kinase binding assay for high throughput screening.", JOURNAL OF BIOMOLECULAR SCREENING, vol. 4, no. 3, June 1999 (1999-06-01), pages 129 - 135, XP001088800, ISSN: 1087-0571
SMITH C C ET AL: "RAS-BINDING AND PHOSPHORYLATION BY HERPES SIMPLEX VIRUS TYPE 2 RR1 PK (ICP10) AND ACTIVATION OF THE RAS/MEK/MAPK MITOGENIC PATHWAY ARE REQUIRED FOR TIMELY ONSET OF VIRUS GROWTH", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 22, November 2000 (2000-11-01), pages 10417 - 10429, XP002185543, ISSN: 0022-538X
SCHNITTLER H-J ET AL: "REPLICATION OF MARBURG VIRUS IN HUMAN ENDOTHELIAL CELLS A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF VIRAL HEMORRHAGIC DISEASE", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 91, no. 4, April 1993 (1993-04-01), pages 1301 - 1309, XP001028245, ISSN: 0021-9738
GUBLER D J: "THE GLOBAL PANDEMIC OF DENGUE/DENGUE HAEMORRHAGIC FEVER: CURRENT STATUS AND PROSPECTS FOR THE FUTURE", ANNALS OF THE ACADEMY OF MEDICINE, SINGAPORE, ACADEMY OF MEDICINE, SG, vol. 27, no. 2, March 1998 (1998-03-01), pages 227 - 234, XP000952639, ISSN: 0304-4602

View/Download PDF      PDF Help

Previous Patent: DEVICE FOR PACKAGING AN OXIPLATINUM SOLUTION

Next Patent: IL-8 RECEPTOR LIGANDS-DRUGS FOR INFLAMMATORY AND AUTOIMMUNE DISEASES